Compare Ascendis Pharma A/S (ASND) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.8 (market cap $141.88B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 8× Ascendis Pharma A/S's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BBVA | |
|---|---|---|
Market Cap | $17.74B | $141.88B |
Sector | Health | Financials |
52-Week High | $277.18 | $26.14 |
52-Week Low | $163.32 | $14.73 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BBVA trades at $25.69, up 1.3% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with 26.51% net income margin and 18.67% ROE, though recent legal challenges from Spain's High Court regarding a spying case present headwinds. Earnings have mostly beaten expectations, with Q1 2026 EPS of $0.60 exceeding the $0.57 forecast.
The stock offers value with a P/E of 12.39 and receives strong analyst support (53.85% buy ratings), but investors should weigh regulatory risks and volatile cash flows against the positive earnings trajectory and technical momentum for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
